Therna Biosciences

Therna Biosciences is a preclinical-stage biotechnology company focused on developing next-generation RNA therapeutics using a proprietary circular RNA (circRNA) platform. Founded by a team of world-renowned RNA biologists, the company aims to overcome the stability and immunogenicity limitations associated with traditional linear mRNA. Their technology engineers RNA into a circular format that is resistant to exonuclease degradation, potentially allowing for more durable protein expression and reduced dosing frequency. Therna is currently advancing a pipeline of programs targeting rare genetic disorders and other conditions where sustained therapeutic protein production is required. The company represents a significant effort to translate foundational RNA research into a new class of potent, long-lasting medicines.